Literature DB >> 18198826

Emerging opportunities for antipsychotic drug discovery in the postgenomic era.

Michael J Marino1, Lars J S Knutsen, Michael Williams.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18198826     DOI： 10.1021/jm701094q

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  6 in total

1.  D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone.

Authors:  Michael Popiolek; John F Ross; Erik Charych; Pranab Chanda; Eckart D Gundelfinger; Stephen J Moss; Nicholas J Brandon; Mark H Pausch
Journal:  J Biol Chem       Date:  2011-06-23       Impact factor: 5.157

2.  TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Authors:  T A Hauser; A Kucinski; K G Jordan; G J Gatto; S R Wersinger; R A Hesse; E K Stachowiak; M K Stachowiak; R L Papke; P M Lippiello; M Bencherif
Journal:  Biochem Pharmacol       Date:  2009-05-29       Impact factor: 5.858

Review 3.  Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.

Authors:  Robert J Harvey; Benjamin K Yee
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

4.  New information of dopaminergic agents based on quantum chemistry calculations.

Authors:  Guillermo Goode-Romero; Ulrika Winnberg; Laura Domínguez; Ilich A Ibarra; Rubicelia Vargas; Elisabeth Winnberg; Ana Martínez
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

Review 5.  Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Authors:  Peng Li; Gretchen L Snyder; Kimberly E Vanover
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

6.  A quantum chemical approach representing a new perspective concerning agonist and antagonist drugs in the context of schizophrenia and Parkinson's disease.

Authors:  Ana Martínez; Ilich A Ibarra; Rubicelia Vargas
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.